Kilcoyne John T 4
4 · MICRUS ENDOVASCULAR CORP · Filed Sep 28, 2010
Insider Transaction Report
Form 4
Kilcoyne John T
DirectorCEO and Chairman of the Board
Transactions
- Disposition to Issuer
Common Stock
2010-09-27−8,056→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−16,692$98,316→ 0 totalExercise: $17.51Exp: 2017-11-12→ Common Stock (16,692 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−3,647$43,691→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (3,647 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−33,647$598,075→ 0 totalExercise: $5.63Exp: 2015-02-23→ Common Stock (33,647 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−1,463$26,005→ 0 totalExercise: $5.63Exp: 2015-02-23→ Common Stock (1,463 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$11.98/sh−31,353$375,609→ 0 totalExercise: $11.42Exp: 2018-05-14→ Common Stock (31,353 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−38,441$546,247→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (38,441 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−71,044$1,262,807→ 0 totalExercise: $5.63Exp: 2014-11-29→ Common Stock (71,044 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$5.89/sh−18,308$107,834→ 0 totalExercise: $17.51Exp: 2017-11-12→ Common Stock (18,308 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$14.21/sh−11,559$164,253→ 0 totalExercise: $9.19Exp: 2019-05-26→ Common Stock (11,559 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2010-09-27$17.77/sh−240,066$4,267,173→ 0 totalExercise: $5.63Exp: 2014-11-29→ Common Stock (240,066 underlying)
Footnotes (3)
- [F1]1,646 shares of common stock were purchased under Micrus Endovascular Corporation's 2005 Employee Stock Purchase Plan as follows: 1,111 shares on March 31, 2010 and 535 shares on September 23, 2010.
- [F2]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., each share of common stock held by the reporting person was converted into the right to receive $23.40 in cash, without interest.
- [F3]Pursuant to the Agreement and Plan of Merger, dated as of July 11, 2010, between Micrus Endovascular Corporation, Johnson & Johnson and Cope Acquisition Corp., this stock option was converted into the right to receive an amount in cash per share subject to the stock option equal to the excess of the per share merger consideration of $23.40 over the per share exercise price of such stock option, without interest.